Observations placeholder

Humulin  - is the brand name for a group of biosynthetic human insulin products, originally developed by Genentech in 1978. It is currently sold by Eli Lilly and according to the company's web site, Humulin is identical in chemical structure to human insulin. Humulin is synthesized in a laboratory strain of Escherichia coli bacteria which has been genetically altered with recombinant DNA to produce biosynthetic human insulin. Humulin by itself is a short-acting insulin, however, the synthesised insulin is then combined with other compounds or types of insulin which affect its shelf life and absorption. 

• Humulin R is a short-acting insulin that has a relatively short duration of activity as compared with other insulins; it consists of zinc-insulin crystals dissolved in a clear fluid. 

• Humulin N is combined with protamine to extend the time-activity profile of Humulin R for an extended period of time; it is an intermediate-acting insulin with a slower onset of action and a longer duration of activity than Humulin R.

• Humulin 70/30 (70% human insulin isophane suspension, 30% human insulin injection [rDNA origin]) is a mixture insulin. It is an intermediate-acting insulin combined with the onset of action of Humulin 

• Humulin 50/50 (50% human insulin isophane suspension, 50% human insulin injection [rDNA origin]) is a mixture insulin. It is an intermediate-acting insulin combined with the onset of action of Humulin R.